Your browser doesn't support javascript.
loading
Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report.
Dwyer, Liam James; Singhal, Nimit; Yu, Bing; Kao, Steven.
Afiliação
  • Dwyer LJ; Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia; Central Clinical School, University of Sydney, Darlington, New South Wales, Australia. Electronic address: liamjames.dwyer@health.nsw.gov.au.
  • Singhal N; Cancer Centre, Royal Adelaide Hospital, Adelaide, South Australia, Australia; Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
  • Yu B; Central Clinical School, University of Sydney, Darlington, New South Wales, Australia; Department of Medical Genomics, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; NSW Health Pathology, Newcastle, New South Wales, Australia.
  • Kao S; Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia; Central Clinical School, University of Sydney, Darlington, New South Wales, Australia.
J Thorac Oncol ; 19(4): 650-652, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38340108
ABSTRACT
Adjuvant osimertinib represents a recent paradigm shift in the management of resected EGFR-mutated lung cancer. The optimal subsequent treatment of patients who relapse after completion of 3 years of adjuvant osimertinib is unknown. Here, we report two cases of complete response to osimertinib rechallenge after relapse from previous adjuvant osimertinib use, and a serial molecular panel exhibiting a lack of acquired resistance mechanisms. Future prospective studies are warranted to confirm the optimal treatment of patients who relapse after previous adjuvant osimertinib.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Pirimidinas / Acrilamidas / Carcinoma Pulmonar de Células não Pequenas / Indóis / Neoplasias Pulmonares Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: J Thorac Oncol Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Pirimidinas / Acrilamidas / Carcinoma Pulmonar de Células não Pequenas / Indóis / Neoplasias Pulmonares Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: J Thorac Oncol Ano de publicação: 2024 Tipo de documento: Article